113 related articles for article (PubMed ID: 2704024)
1. Analogues of cisplatin derived from diaminodideoxytetritols. Synthesis and activity against the ADJ/PC6 plasmacytoma in mice.
Haines AH; Morley C; Murrer BA
J Med Chem; 1989 Apr; 32(4):742-5. PubMed ID: 2704024
[TBL] [Abstract][Full Text] [Related]
2. Platinum coordination complexes which circumvent cisplatin resistance.
Harrap KR; Kelland LR; Jones M; Goddard PM; Orr RM; Morgan SE; Murrer BA; Abrams MJ; Giandomenico CM; Cobbleigh T
Adv Enzyme Regul; 1991; 31():31-43. PubMed ID: 1877393
[TBL] [Abstract][Full Text] [Related]
3. cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice.
Raynaud FI; Boxall FE; Goddard PM; Valenti M; Jones M; Murrer BA; Abrams M; Kelland LR
Clin Cancer Res; 1997 Nov; 3(11):2063-74. PubMed ID: 9815598
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and in vitro and in vivo antitumor activity of a series of trans platinum antitumor complexes.
Kelland LR; Barnard CF; Evans IG; Murrer BA; Theobald BR; Wyer SB; Goddard PM; Jones M; Valenti M; Bryant A
J Med Chem; 1995 Aug; 38(16):3016-24. PubMed ID: 7636864
[TBL] [Abstract][Full Text] [Related]
5. Structure and activity relationships of platinum complexes with anti-tumour activity.
Braddock PD; Connors TA; Jones M; Khokhar AR; Melzack DH; Tobe ML
Chem Biol Interact; 1975 Sep; 11(3):145-61. PubMed ID: 1157188
[TBL] [Abstract][Full Text] [Related]
6. The role of glutathione (GSH) in determining sensitivity to platinum drugs in vivo in platinum-sensitive and -resistant murine leukaemia and plasmacytoma and human ovarian carcinoma xenografts.
Goddard P; Valenti M; Kelland LR
Anticancer Res; 1994; 14(3A):1065-70. PubMed ID: 8074451
[TBL] [Abstract][Full Text] [Related]
7. Metabolism, protein binding and in vivo activity of the oral platinum drug JM216 and its biotransformation products.
Raynaud FI; Boxall FE; Goddard P; Barnard CF; Murrer BA; Kelland LR
Anticancer Res; 1996; 16(4A):1857-62. PubMed ID: 8712713
[TBL] [Abstract][Full Text] [Related]
8. Novel trans platinum complexes: comparative in vitro and in vivo activity against platinum-sensitive and resistant murine tumours.
Goddard PM; Orr RM; Valenti MR; Barnard CF; Murrer BA; Kelland LR; Harrap KR
Anticancer Res; 1996; 16(1):33-8. PubMed ID: 8615631
[TBL] [Abstract][Full Text] [Related]
9. Preclinical antitumor evaluation of bis-acetato-ammine-dichloro-cyclohexylamine platinum(IV): an orally active platinum drug.
Kelland LR; Abel G; McKeage MJ; Jones M; Goddard PM; Valenti M; Murrer BA; Harrap KR
Cancer Res; 1993 Jun; 53(11):2581-6. PubMed ID: 8388318
[TBL] [Abstract][Full Text] [Related]
10. The role of murine tumour models and their acquired platinum-resistant counterparts in the evaluation of novel platinum antitumour agents: a cautionary note.
Goddard PM; Valenti MR; Harrap KR
Ann Oncol; 1991 Sep; 2(8):535-40. PubMed ID: 1793720
[TBL] [Abstract][Full Text] [Related]
11. The tumor-inhibiting effect of isomeric dichloro(diphenylethylenediamine)platinum(II) complexes.
Wappes B; Jennerwein M; von Angerer E; Engel J; Schönenberger H; Brunner H; Schmidt M; Berger M; Schmähl D; Seeber S
J Cancer Res Clin Oncol; 1984; 107(1):15-20. PubMed ID: 6538199
[TBL] [Abstract][Full Text] [Related]
12. Preclinical anti-tumor activity of a new oral platinum(IV) drug LA-12.
Sova P; Mistr A; Kroutil A; Zak F; Pouckova P; Zadinova M
Anticancer Drugs; 2005 Jul; 16(6):653-7. PubMed ID: 15930894
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of therapeutic doses of isotopically labeled platinum antitumor agents in the mouse and rat.
Robins AB; Leach MO
Cancer Treat Rep; 1983 Mar; 67(3):245-52. PubMed ID: 6682013
[TBL] [Abstract][Full Text] [Related]
14. The 5-HT3 antagonist, BRL 43694, does not compromise the efficacy of cisplatin in tumour-bearing mice.
Goddard PM; Jones M; Pollard LA; Valenti MR; Harrap KR
Cancer Chemother Pharmacol; 1990; 25(5):377-9. PubMed ID: 2155065
[TBL] [Abstract][Full Text] [Related]
15. The metabolism and antitumour activity of the enantiomers of cis- and trans-4-methylcyclophosphamide.
Farmer PB; Jarman M; Facchinetti T; Pankiewicz K; Stec WJ
Chem Biol Interact; 1977 Jul; 18(1):47-57. PubMed ID: 890840
[TBL] [Abstract][Full Text] [Related]
16. Preclinical pharmacology and antitumour activity of the novel sequence-selective DNA minor-groove cross-linking agent DSB-120.
Walton MI; Goddard P; Kelland LR; Thurston DE; Harrap KR
Cancer Chemother Pharmacol; 1996; 38(5):431-8. PubMed ID: 8765436
[TBL] [Abstract][Full Text] [Related]
17. Chemical and biological properties of a new series of cis-diammineplatinum(II) antitumor agents containing three nitrogen donors: cis-[Pt(NH3)2(N-donor)Cl]+.
Hollis LS; Amundsen AR; Stern EW
J Med Chem; 1989 Jan; 32(1):128-36. PubMed ID: 2909724
[TBL] [Abstract][Full Text] [Related]
18. Schedule dependency of orally administered bis-acetato-ammine-dichloro-cyclohexylamine-platinum(IV) (JM216) in vivo.
McKeage MJ; Kelland LR; Boxall FE; Valenti MR; Jones M; Goddard PM; Gwynne J; Harrap KR
Cancer Res; 1994 Aug; 54(15):4118-22. PubMed ID: 8033145
[TBL] [Abstract][Full Text] [Related]
19. [Structure-activity relations of antineoplastic platinum II and platinum IV coordination compounds].
Gutsche W; Baumgart J; Schröer HP
Arch Geschwulstforsch; 1989; 59(4):233-8. PubMed ID: 2802931
[TBL] [Abstract][Full Text] [Related]
20. A novel trans-platinum coordination complex possessing in vitro and in vivo antitumor activity.
Kelland LR; Barnard CF; Mellish KJ; Jones M; Goddard PM; Valenti M; Bryant A; Murrer BA; Harrap KR
Cancer Res; 1994 Nov; 54(21):5618-22. PubMed ID: 7923207
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
